10-Nov-2009 - Compugen, Ltd.

Compugen Announces Preeclampsia Biomarker Collaboration

Collaboration Based on Compugen Discovered VEGF Receptor Splice Variant

Compugen Ltd. announced that it has signed a research and license agreement with a diagnostic company covering CGEN-226, a biomarker candidate for early detection of preeclampsia. Preeclampsia is the most common of the dangerous pregnancy complications, occurring in 5-8% of all pregnancies, with potentially very serious effects for both the mother and the fetus. For competitive reasons, the diagnostic company requested that their identity not be disclosed.

At present, attempts at early diagnosis of preeclampsia rely largely on symptoms which are non-specific to the disease. If the condition is not recognized, and the pregnancy is left to continue to full term, the disease will progress to eclampsia, often resulting in seizure, coma and mortality. Therefore, diagnosing preeclampsia in the early stages of a pregnancy is a field of high interest to the medical community and diagnostic industry.

CGEN-226 is a soluble splice variant of the vascular endothelial growth factor (VEGF) receptor 1 gene. This previously unknown splice variant was predicted and selected through the use of Compugen’s in silico modeling of the human transcriptome and proteome for the discovery of novel molecules for diagnostic and therapeutic uses. Following its in silico prediction and selection, CGEN-226 was validated experimentally, and patent applications covering this novel splice variant were made for various diagnostic and therapeutic applications.

Prior to the Compugen discovery and validation of CGEN-226, a different soluble form of the VEGF receptor 1 was shown to be produced by the placenta and to be elevated in the blood stream of pregnant women who develop preeclampsia. However, the Compugen discovered CGEN-226 has subsequently been shown to be the primary soluble VEGF receptor 1 in the circulation of women with preeclampsia. This finding further supports Compugen’s prediction that this variant is a candidate biomarker suitable to serve as a basis for a diagnostic test discriminating normal pregnancy and that with preeclampsia, even prior to clinical manifestation.

Facts, background information, dossiers
More about Compugen
  • News

    Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement

    Medarex, Inc. and Compugen Ltd. have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases. Under the terms of the agreement, Medarex and Compugen plan to share discovery, development and commercialization respons ... more

    Compugen Appoints Eli Zangvil, MD, as Vice President Business Development

    Compugen Ltd. announced the appointment of Eli Zangvil, MD, as Vice President, Business Development. In this position, Dr. Zangvil will join the Commercial Operations team with management responsibility for selected strategic alliance and business development activities. In his role, Dr. Z ... more

    Compugen Leads Consortium to Model Cancer Related Kinase Pathway

    Compugen Ltd. announced that it is leading a consortium for the development of a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer which is already targeted by a number of cancer therapies and diagnostic tests. The Simulation Modeling of the MAP-kinase Path ... more

  • Companies

    Compugen, Ltd.

    Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focu ... more